We then analyzed BM levels of IL-6, the main MM pro-survival factor (36), which is also involved in PD-L1 up-regulation on monocytes (37) and recently described as predictor of response to PD-L1/PD-1 inhibitors in NSCLC patients (38). Here, IL6 is linked to Miyoshi myopathy.